Complications of Subspecialty Ophthalmic Care: Endophthalmitis after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Medications

References

• Ramulu PY, Do DV, Corcoran KJ, et al. Use of retinal procedures in medicare beneficiaries from 1997 to 2007. Arch Ophthalmol 2010;128:1335–1340
   PubMedGoogle Scholar
• , Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupMartin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388–1398
   PubMed Web of Science ®Google Scholar
• Brown DM, Campochiaro PA, Singh RP, et al. CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1124–1133
   PubMed Web of Science ®Google Scholar
• Brown DM, Nguyen QD, Marcus DM, et al. RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120:2013–2022
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537–2548
   PubMed Web of Science ®Google Scholar
• Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) 2013;27:787–794
   PubMed Web of Science ®Google Scholar
• McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 2011;31:654–661
   PubMed Web of Science ®Google Scholar
• Fileta JB, Scott IU, H W FlynnJr. Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina 2014;45:143–149
   PubMed Web of Science ®Google Scholar
• Moshfeghi AA, Rosenfeld PJ, H W Flynn Jret al. Endophthalmitis after intravitreal vascular endothelial growth factor antagonists: a six-year experience at a university referral center. Retina 2011;31:662–668
   PubMed Web of Science ®Google Scholar
• Englander M, Chen TC, Paschalis EI, et al. Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates. Br J Ophthalmol 2013;97:460–465
   PubMed Web of Science ®Google Scholar
• Lyall DA, Tey A, Foot B, et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye (Lond) 2012;26:1517–1526
   PubMed Web of Science ®Google Scholar
• The Endophthalmitis Vitrectomy Study Group. Microbiologic factors and visual outcome in the endophthalmitis vitrectomy study. Am J Ophthalmol 1996;122:830–846
   PubMed Web of Science ®Google Scholar
• Lalwani GA, Flynn HW, Scott IU. Acute-onset endophthalmitis after clear corneal cataract surgery (1996–2005): Clinical features, causative organisms, and visual acuity outcomes. Ophthalmology 2008;115:473–476
   PubMed Web of Science ®Google Scholar
• Jacobs DJ, Leng T, Flynn HW, et al. Delayed-onset bleb-associated endophthalmitis: presentation and outcome by culture result. Clin Ophthalmol 2011;5:739–744
   PubMedGoogle Scholar
• Leng T, Miller D, Flynn HW, et al. Delayed-onset bleb-associated endophthalmitis (1996–2008): causative organisms and visual acuity outcomes. Retina 2011;31:344–352
   PubMed Web of Science ®Google Scholar
• Wen JC, McCannel CA, Mochon AB, et al. Bacterial dispersal associated with speech in the setting of intravitreous injections. Arch Ophthalmol 2011;12:1551–1554
   Google Scholar
• Wykoff CC, Flynn HW. Endophthalmitis after intravitreal injection: prevention and management. Retina 2011;31:633–635
   PubMed Web of Science ®Google Scholar
• Chaudhary K, Romero JM, Ezon I, et al. Pars plana vitrectomy in the management of patients diagnosed with endophthalmitis following intravitreal anti-vascular endothelial growth factor injection. Retina 2013;33:1407–1416
   PubMed Web of Science ®Google Scholar
• Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis: Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol 1995;113:1479–1496
   PubMedGoogle Scholar
• Goldberg RA, Flynn HW, Miller D, et al. Streptococcus endophthalmitis outbreak after intravitreal injection of bevacizumab: One-year outcomes and investigative results. Ophthalmology 2013;120:1448–1453
   PubMed Web of Science ®Google Scholar
• Schimel AM, Scott IU, H W Flynn Jr. Endophthalmitis after intravitreal injections: Should the use of face masks be the standard of care? Arch Ophthalmol 2011;129:1607–1609
   PubMedGoogle Scholar
• , VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupChakravarthy U, Adamis AP, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113:1508–1525
   PubMed Web of Science ®Google Scholar
• Storey P, Dollin M, Pitcher J, et al. Post-Injection Endophthalmitis Study Team. The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection. Ophthalmology 2014;121:283–289
   PubMed Web of Science ®Google Scholar
• Cheung CS, Wong AW, Lui A, et al. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology 2012;119:1609–1614
   PubMed Web of Science ®Google Scholar
• Chen RW, Rachitskaya A, Scott IU, et al. Is the use of topical antibiotics for intravitreal injections the standard of care or are we better off without antibiotics? JAMA Ophthalmol 2013;131:840–842
   PubMed Web of Science ®Google Scholar
• Bhavsar AR, Stockdale CR, Ferris FL, et al. Diabetic Retinopathy Clinical Research Network. Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics. Arch Ophthalmol 2012;130:809–810
   PubMed Web of Science ®Google Scholar
• Ahmed Y, Scott IU, Pathengay A, et al. Povidone-iodine for endophthalmitis prophylaxis. Am J Ophthalmol 2014;157:503–504
   PubMed Web of Science ®Google Scholar
• Hsu J, Gerstenblith AT, Garg SJ, et al. Conjunctival flora antibiotic resistance patterns after serial intravitreal injections without postinjection topical antibiotics. Am J Ophthalmol 2014;157:514–518
   PubMed Web of Science ®Google Scholar
• D'Amico DJ, Masonson HN, Patel M, et al. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group: Pegaptanib sodium for neovascular age-related macular degeneration: Two year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113:992–1001
   PubMed Web of Science ®Google Scholar
• Friedman DA, Mason JO, Emond T, et al. Povidone-iodine contact time and lid speculum use during intravitreal injection. Retina 2013;33:975–981
   PubMed Web of Science ®Google Scholar
• Fineman MS, Hsu J, Spirn MJ, et al. Bimanual assisted eyelid retraction technique for intravitreal injections. Retina 2013;33:1968–1970
   PubMed Web of Science ®Google Scholar
• Goldberg RA, Flynn HW, Isom RF, et al. An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol 2012;153
   Google Scholar
• Gonzalez S, Rosenfeld PJ, Stewart MW, et al. Avastin doesn't blind people, people blind people. Am J Ophthalmol 2012;153:196–203
   PubMed Web of Science ®Google Scholar